Pathchooser
Initial Training Network (ITN) granted by the Marie Skłodowska-Curie Actions (mobility research grants created by the European Union/European Commission to support European research). The full name of the network is Innovative, mechanistic-based strategies for delivery of therapeutic macromolecules across cellular and biological barriers. The purpose of PathChooser is to equip the next generation of translational scientists with the tools to develop therapies for a range of currently intractable (e.g. hidden in the brain) and economically unviable diseases (e.g. orphan diseases affecting a limited population).
Project
The first aim of the project is to understand endocytotic, transcytotic, and other cellular processes, especially biological barrier crossing. The second purpose is to elucidate the mechanism of successful delivery systems (beyond current level) will ensure more rapid regulatory and general acceptance of such medicines. This is achieved by the design and characterization of the in situ interface between the carrier system and the uptake, and signaling machinery. The network strength is an inter-disciplinary knowledge from a range of scientific disciplines that is required to launch a genuine attack on the therapeutic challenge.
Partners, fellows, tutors, and research projects
Partner name |
Partner short name |
Country |
Fellow |
Tutor |
Research project |
|---|---|---|---|---|---|
University College Dublin |
UCD |
Ireland |
Luciana-Maria Herda |
Prof. Kenneth A. Dawson |
Designing the bionanointerface for transcytosis and barrier crossing |
University College Dublin |
UCD |
Ireland |
Diana Hudecz |
Prof. Kenneth A. Dawson |
From endocytosis to transcytosis: investigation of key steps and signals |
University of Southern Denmark |
SDU |
Denmark |
Martina Tuttolomondo |
Prof. Dr. Jan Mollenhauer |
Harnessing Natural Pattern Recognition Mechanisms for Macromolecular [...] Delivery |
HZI |
Germany |
Xabier Murgia Esteve |
Prof. Dr. Claus-Michael Lehr |
Interaction of nanoparticles with the pulmonary barrier; the role of mucus in health and disease |
|
Kings College London |
KCL |
United Kingdom |
Anne Iltzsche |
Prof. Dr. David Begley |
Apolipoprotein E and A targeted albumin nanoparticle delivery to the CNS: Mechanism and route of delivery |
EPOS IASIS |
Cyprus |
Ahmed Eladly |
Dr. Andreani Odysseos |
Optimizing the transport of nanoparticles through mucus secreting cancers. |
|
Max Planck Institute of Molecular Cell Biology and Genetics |
MPI-CBG |
Germany |
Prasath Paramasivam |
Prof. Dr. Marino Zerial |
Development of bio-inspired routes for delivery of siRNAs |
University of Manchester |
UNIMA |
United Kingdom |
Marilena Hadjidemetriou |
Prof. Dr. Kostas Kostarelos |
Design of degradable targeted nanoparticle-based delivery vehicles |
University of Bristol |
UNIVBRIS |
United Kingdom |
Catherine Gilmore |
Prof. Dr. Patrick Case |
Nanoparticle exposure of placental barriers – an indirect route of teratogenesis |
ACS |
United Kingdom |
Dr. Maria Rita Fabbrizi |
Dr. Colin J Wilde |
Cell-Based Nanosafety Assay Design and Validation for Accreditation and Dissemination |
|
EPOS IASIS |
Cyprus |
Dr. Nikolaos Mandalos |
Dr. Andreani Odysseos |
Experimental testing of nanoparticulate systems for crossing intact and disrupted barriers |
Other information
Project title: PathChooser: Initial Training Networks
Project acronym: PathChooser
Duration: from 1 October 2013 to 30 September 2017 (4 years)
Program: FP7-PEOPLE-2013-ITN (Marie-Curie Initial Training Networks)
Grant Agreement Number: 608373 (PITN-GA-2013-608373)
Profile in CORDIS: PathChooser